专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07745619B2 Vinca derivatives 有权
标题翻译：长春花衍生物
公开(公告)号：US07745619B2
公开(公告)日：2010-06-29
申请号：US11933259
申请日：2007-10-31
申请人： Ian L. Scott , Jeffrey M. Ralph , Matthew E. Voss
发明人： Ian L. Scott , Jeffrey M. Ralph , Matthew E. Voss
IPC分类号： C07D245/00
CPC分类号： C07D519/04
摘要： The present invention relates to derivatives of vinca alkaloids. Pharmaceutical compositions containing these compounds as well as processes of preparation and treatment of various conditions are also disclosed.
摘要翻译：本发明涉及长春花生物碱的衍生物。还公开了含有这些化合物的药物组合物以及各种条件的制备和处理方法。

2. 发明授权

US07235564B2 Vinorelbine derivatives 失效
标题翻译：长春瑞滨衍生物
公开(公告)号：US07235564B2
公开(公告)日：2007-06-26
申请号：US11003583
申请日：2004-12-03
申请人： Ian L. Scott , Jeffrey M. Ralph , Matthew E. Voss
发明人： Ian L. Scott , Jeffrey M. Ralph , Matthew E. Voss
IPC分类号： A61P35/00 , A61K31/4745 , C07D487/22
CPC分类号： C07D519/00 , C07D519/04
摘要： The present invention relates to novel vinorelbine derivatives. Pharmaceutical compositions containing these compounds as well as processes of preparation and processes of use for treatment of various conditions are also disclosed.
摘要翻译：本发明涉及新的长春瑞滨衍生物。还公开了含有这些化合物的药物组合物以及制备方法和用于治疗各种病症的用途。

3. 发明授权

US07842802B2 Vinorelbine derivatives 有权
标题翻译：长春瑞滨衍生物
公开(公告)号：US07842802B2
公开(公告)日：2010-11-30
申请号：US12331691
申请日：2008-12-10
申请人： Ian L. Scott , Jeffrey M. Ralph , Matthew E. Voss
发明人： Ian L. Scott , Jeffrey M. Ralph , Matthew E. Voss
IPC分类号： C07D487/00 , C07D491/00 , C07D513/00
CPC分类号： C07D519/00 , C07D519/04
摘要： The present invention relates to novel vinorelbine derivatives. Pharmaceutical compositions containing these compounds as well as processes of preparation and processes of use for treatment of various conditions are also disclosed.
摘要翻译：本发明涉及新的长春瑞滨衍生物。还公开了含有这些化合物的药物组合物以及制备方法和用于治疗各种病症的用途。

4. 发明授权

US07238704B2 Vinca derivatives 有权
标题翻译：长春花衍生物
公开(公告)号：US07238704B2
公开(公告)日：2007-07-03
申请号：US11003560
申请日：2004-12-03
申请人： Ian L. Scott , Jeffrey M. Ralph , Matthew E. Voss
发明人： Ian L. Scott , Jeffrey M. Ralph , Matthew E. Voss
IPC分类号： A61P35/00 , A61K31/4745 , C07D487/22
CPC分类号： C07D519/04
摘要： The present invention relates to derivatives of vinca alkaloids. Pharmaceutical compositions containing these compounds as well as processes of preparation and treatment of various conditions are also disclosed.
摘要翻译：本发明涉及长春花生物碱的衍生物。还公开了含有这些化合物的药物组合物以及各种条件的制备和处理方法。

5. 发明授权

US08895543B2 Vinca derivatives 有权
标题翻译：长春花衍生物
公开(公告)号：US08895543B2
公开(公告)日：2014-11-25
申请号：US11697415
申请日：2007-04-06
申请人： Ian L. Scott , Jeffrey M. Ralph , Matthew E. Voss
发明人： Ian L. Scott , Jeffrey M. Ralph , Matthew E. Voss
IPC分类号： A61K31/33 , A61K31/395 , C07D519/04
CPC分类号： C07D519/04
摘要： The present invention relates to derivatives of vinca alkaloids. Pharmaceutical compositions containing these compounds as well as processes of preparation and treatment of various conditions are also disclosed.
摘要翻译：本发明涉及长春花生物碱的衍生物。还公开了含有这些化合物的药物组合物以及各种条件的制备和处理方法。

6. 发明申请

US20090088568A1 VINORELBINE DERIVATIVES 有权
标题翻译：葡萄糖衍生物
公开(公告)号：US20090088568A1
公开(公告)日：2009-04-02
申请号：US12331691
申请日：2008-12-10
申请人： Ian L. Scott , Jeffrey M. Ralph , Matthew E. Voss
发明人： Ian L. Scott , Jeffrey M. Ralph , Matthew E. Voss
IPC分类号： C07D491/14
CPC分类号： C07D519/00 , C07D519/04
摘要： The present invention relates to novel vinorelbine derivatives. Pharmaceutical compositions containing these compounds as well as processes of preparation and processes of use for treatment of various conditions are also disclosed.
摘要翻译：本发明涉及新的长春瑞滨衍生物。还公开了含有这些化合物的药物组合物以及制备方法和用于治疗各种病症的用途。

7. 发明授权

US08053428B2 Vinorelbine derivatives 失效
标题翻译：长春瑞滨衍生物
公开(公告)号：US08053428B2
公开(公告)日：2011-11-08
申请号：US11697370
申请日：2007-04-06
申请人： Ian L. Scott , Jeffrey M. Ralph , Matthew E. Voss
发明人： Ian L. Scott , Jeffrey M. Ralph , Matthew E. Voss
IPC分类号： A61K31/33
CPC分类号： C07D519/00 , C07D519/04
摘要： The present invention relates to novel vinorelbine derivatives. Pharmaceutical compositions containing these compounds as well as processes of preparation and processes of use for treatment of various conditions are also disclosed.
摘要翻译：本发明涉及新的长春瑞滨衍生物。还公开了含有这些化合物的药物组合物以及制备方法和用于治疗各种病症的用途。

8. 发明授权

US08222421B2 Certain substituted ureas, as modulators of kinase activity 有权
标题翻译：某些取代的脲，作为激酶活性的调节剂
公开(公告)号：US08222421B2
公开(公告)日：2012-07-17
申请号：US12840246
申请日：2010-07-20
申请人： Scott A. Mitchell , Mihaela Diana Danca , Peter A. Blomgren , David R. Brittelli , Pavel Zhichkin , Matthew E. Voss
发明人： Scott A. Mitchell , Mihaela Diana Danca , Peter A. Blomgren , David R. Brittelli , Pavel Zhichkin , Matthew E. Voss
IPC分类号： C07D215/38
CPC分类号： C07D471/04 , C07D401/06
摘要： Certain chemical entities chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, and prodrugs thereof, are provided herein. Pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicles chosen from carriers, adjuvants, and excipients, are also provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to angiogenic kinase modulation, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include cancer, including breast neoplasia, endometrial cancer, colon cancer, and neck squamous cell carcinoma. Methods of treatment include administering at least one chemical entity as a single active agent or administering such at least one chemical entity in combination with one or more other therapeutic agents. A method for determining the presence or absence of an angiogenic kinase in a sample comprising contacting the sample with at least one chemical entity under conditions that permit detection of activity of the angiogenic kinase, detecting a level of the activity of the angiogenic kinase, and therefrom determining the presence or absence of the angiogenic kinase in the sample.
摘要翻译：本文提供了选自式1化合物的某些化学实体及其药学上可接受的盐，溶剂合物，螯合物，非共价复合物及其前体药物。还提供了包含至少一种化学实体和一种或多种选自载体，佐剂和赋形剂的药学上可接受的载体的药物组合物。公开了治疗患有对血管生成激酶调节反应的某些疾病和病症的患者的方法，其包括向这些患者施用一定量的至少一种有效减少疾病或病症体征或症状的化学实体。这些疾病包括癌症，包括乳腺肿瘤，子宫内膜癌，结肠癌和颈部鳞状细胞癌。治疗方法包括给予至少一种化学实体作为单一活性剂或者与一种或多种其它治疗剂组合施用这样的至少一种化学实体。一种用于确定样品中存在或不存在血管生成激酶的方法，包括在允许检测血管生成激酶活性，检测血管生成激酶活性水平的条件下将样品与至少一种化学实体接触确定样品中存在或不存在血管生成激酶。

9. 发明授权

US5414004A Neurotransmitter releasers useful for cognition enhancement 失效
标题翻译：神经递质释放剂可用于认知增强
公开(公告)号：US5414004A
公开(公告)日：1995-05-09
申请号：US124523
申请日：1993-09-20
申请人： Wendell W. Wilkerson , Richard A. Earl , Matthew E. Voss
发明人： Wendell W. Wilkerson , Richard A. Earl , Matthew E. Voss
IPC分类号： C07D239/26 , A61K31/44 , A61K31/4409 , A61K31/4418 , A61K31/4427 , A61K31/443 , A61K31/495 , A61P25/28 , C07D213/24 , C07D213/44 , C07D213/50 , C07D213/55 , C07D213/57 , C07D213/61 , C07D241/12 , C07D401/06 , C07D403/06 , C07D405/06 , C07D405/12 , C07D401/14
CPC分类号： C07D401/06 , C07D213/50 , C07D213/55 , C07D213/57 , C07D403/06 , C07D405/06
摘要： Compounds of the following formula have been shown to enhance the release of the neurotransmitter acetylcholine, and thus may be useful in the treatment of diseases of man involving learning and cognition, where subnormal levels of this neurochemical are found ##STR1## wherein R.sup.1 is 4-,3-, or 2-pyridyl, 2-fluoro-4-pyridyl or 3-fluoro-4-pyridyl;R.sup.2 is alkyl of 1 to 10 carbons, cycloalkyl of 3 to 8 carbons, 2-,3-, or 4-pyridyl, Phe or Phe-W;Phe is a phenyl group;W is F, Cl, Br, R.sup.4, --OH, --OR.sup.4, --NO.sub.2, --NH.sub.2, --NHR.sup.4, --NR4R.sup.4, --CN, --S(O)m --R.sup.4 ;R.sup.3 is H, F, Cl, Br, --CN, --OH, --NO.sub.2, --NH.sub.2, --CF.sub.3, --NHR.sup.4, --NR.sup.4 R.sup.4, R.sup.4, --OR.sup.4, --S(O).sub.m --R.sup.4R.sup.4 is alkyl of 1 to 4 carbons, CH.sub.2 Phe-- or Phe--;R.sup.5 is --(CH.sub.2).sub.n --Y or --OCOR.sup.4 ;Y is NH.sub.2, --NHR.sup.4, --NR.sup.4 R.sup.4, --NHCOR.sup.4, --NHCO.sub.2 R.sup.4, F, Cl, Br, OR.sup.4, --S(O).sub.m R.sup.4, --CO.sub.2 H, --CO.sub.2 R.sup.4, --CN, --CONR.sup.4 R.sup.4, --CON HR.sup.4, CONHR.sup.4, --CONH.sub.2, --COR.sup.4 ; --CH.dbd.CHCO.sub.2 R.sup.4, OCOR.sup.4, CO.tbd.CCO.sub.2 R.sup.4, --CH.dbd.CHR.sup.4, or --C.tbd.CR.sup.4 ;m is 0, 1 or 2;n is 1 to 7;and physiologically suitable salts thereof.
摘要翻译：已经显示下式的化合物增强神经递质乙酰胆碱的释放，因此可用于治疗涉及学习和认知的人的疾病，其中发现该神经化学物质的次正常水平其中R1是4- ，3-或2-吡啶基，2-氟-4-吡啶基或3-氟-4-吡啶基; R2是1至10个碳的烷基，3至8个碳原子的环烷基，2-，3-或4-吡啶基，Phe或Phe-W; Phe是苯基; W是F，Cl，Br，R 4，-OH，-OR 4，-NO 2，-NH 2，-NHR 4，-NR 4 R 4，-CN，-S（O）m -R 4; R3是H，F，Cl，Br，-CN，-OH，-NO2，-NH2，-CF3，-NHR4，-NR4R4，R4，-OR4，-S（O）m -R4 R4是1〜 4个碳，CH2Phe-或Phe-; R5是 - （CH2）n-Y或-OCOR4; Y是NH 2，-NHR 4，-NR 4 R 4，-NHCOR 4，-NHCO 2 R 4，F，Cl，Br，OR 4，-S（O）m R 4，-CO 2 H，-CO 2 R 4，-CN，-CONR 4 R 4，-CON HR 4，CONHR 4， CONH2，-COR4; -CH = CHCO 2 R 4，OCOR 4，CO 3，CCO 2 R 4，-CH = CHR 4或-C 3 CH 3 CR 4; m为0,1或2; n为1〜7; 和其生理适合的盐。

10. 发明申请

US20150368247A1 2,6,7 SUBSTITUTED PURINES AS HDM2 INHIBITORS 有权
标题翻译： 2,6,7个替代品作为HDM2抑制剂
公开(公告)号：US20150368247A1
公开(公告)日：2015-12-24
申请号：US14764616
申请日：2014-02-04
申请人： Matthew P. CHRISTOPHER , Francesc Xavier FRADERA LLINAS , Michelle MACHACEK , Michelle MARTINEZ , Michael Hale REUTERSHAN , Manami SHIZUKA , Binyuan SUN , Christopher Francis THOMPSON , Wesley B. TROTTER , Matthew E. VOSS , Liping YANG , Merck Sharp & Dohme Corp.
发明人： Matthew P. Christopher , Francesc Xavier Fradera Llinas , Michelle Machacek , Michelle Martinez , Michael Hale Reutershan , Manami Shizuka , Binyuan Sun , Christopher Francis Thompson , B. Wesley Trotter , Matthew E. Voss , Liping Yang
IPC分类号： C07D473/34 , C07D473/00 , C07D473/30
CPC分类号： C07D473/34 , C07D473/00 , C07D473/30
摘要： The present invention provides 2,6,7 substituted purines as described herein or a pharmaceutically acceptable salt thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.
摘要翻译：本发明提供2,6,7本文所述的取代嘌呤或其药学上可接受的盐。代表性化合物可用作HDM2蛋白的抑制剂。还公开了包含上述化合物的药物组合物和使用其治疗癌症的潜在方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式